Objective: The objective of this study was to compare the outcomes of antiretroviral therapy (ART) between hospital and health center levels in Ethiopia. Methods: Medical records of 1709 ART patients followed for 24 months at 2 hospitals and 3 health centers in the Oromia region of Ethiopia were reviewed. Noted outcomes of ART were currently alive and on treatment; lost to follow-up (LTFU); transferred out (TO); and died (D). Results: Of 1709 HIV-positive patients started on ART between September 2006 and February 2007, 1044 remained alive and were on treatment after 24-month follow-up. In all, 835 (57%) of ART patients at hospitals and 209 (83%) at health centers were retained in the program. Of those who were alive and receiving ART, 79% of patients at health centers and 72% at hospitals were clinically or immunologically improving. In addition, 331 (23%) patients at hospitals were LFTU as compared to 24 (10%) of patients at health centers (relative risk [RR] at 95% confidence interval ). While 11% was the mortality rate at hospitals, 5% of patients at health centers also died (RR at 95% CI: .360 [.192-.673]). Conclusion: Antiretroviral therapy at health centers was associated with more favorable outcomes than at hospitals.
Introduction
According to a 2008 Joint United Nations Programme on HIV/ AIDS (UNAIDS) report, 33.2 million people around the world were living with HIV. The report also showed that sub-Saharan Africa was the epicenter of the epidemic, harboring 68% of all HIV-positive people. In the East African countries, the epidemic stabilized because of the high mortality among HIVpositive population, which was about the same as new HIV infection. 1 Considerable improvement in survival of patients living with HIV (PLHIVs) was seen after the inception of antiretroviral treatment (ART) services. 2, 3 For instance, a study conducted in Haiti showed that 1-year survival of a person with AIDS was 30% without ART use. However, the 1-year survival increased to 90% after the effective use of ART. 3, 4 In addition, several studies showed that ART dramatically improves immunological response to AIDS-related diseases. 5 The main challenge is the disproportionate concentration of the epidemic in sub-Saharan Africa. In this region, an underresourced health sector and a dire human resource situation contribute to a slow and ineffective implementation of HIV prevention and control programs. 1 Thus, focused response is needed to enhance health systems and establish effective programs in this region. 6 Ethiopia is one of the countries that have been ravaged by a wave of HIV infections. Since HIV has surfaced, the epidemic has claimed hundreds of thousands of lives. 7 In 2007, the UNAIDS estimated that 980 000 people in Ethiopia were living with HIV. 1 While 242 500 were in need of ART in 2005, 40% of them were living in rural areas with limited access to health care. 8 There were 134 500 HIV-related deaths in 2005 in the country. 9 After a sharp focus on HIV prevention and a piecemeal feebased ART service provision for years, free ART service was launched in the country in 2005 and eventually a phased expansion of care and treatment to all hospitals was made. 10 However, the majority of the rural populations were living beyond the catchment of the ART hospitals. In addition, the financial burden of travel to a distant hospital, missed work hours, and accommodation costs in similar resource-constrained settings were reported as principal reasons for the low enrollment in HIV care and treatment. 11, 12 Besides, limiting the service to hospitals had negative implications on the involvement of the community, notably PLHIVs. Evidence showed that the decentralization of ART resuscitated the quality of the general health services at primary health care where resources were scarce. The positive outcomes reported the included improvement of the human resources and infrastructure development, supply management, diagnostic services, monitoring, and evaluation. 13, 14 In 2006, the Federal HIV/AIDS Prevention and Control Office took a landmark step in collaboration with indigenous and international stakeholders to decentralize ART from mostly urban hospitals to health centers. Thus, ''innovator'' health centers in all regions took the first initiative to render ART to eligible HIV-positive rural Ethiopians. Subsequently, hospitals with severe human resource limitations were decongested by transferring out some patients to nearby health centers. To the best of the author's knowledge, no study was previously conducted to compare the outcomes of ART at hospital and health center levels. However, comparison of patient retention in care and treatment at hospital and clinics 14 and evaluation of cost and outcomes of ART at different models of public and private treatment sites have been conducted in South Africa. 15 In the process of rapid expansion of access to care and treatment, it is imperative to evaluate outcomes of ART at hospital and health center levels. The World Health Organization (WHO) recommends that retention in care and treatment can be used as a standard measure of the effectiveness of an ART program. 16 The objective of this study was to investigate the difference in outcomes of ART service between hospital and health center levels.
Methods
This descriptive study was conducted in the Oromia region of Ethiopia. The region ranks second among all the regions of Ethiopia in the number of PLHIVs, with a third of HIVpositive persons nationwide living in this region. 8 In this study, the outcomes of ART at hospital and health center levels were compared. The 2 levels of HIV treatment chosen had certain similarities that justified a sensible comparison. Both levels followed the same national ART clinical guidelines, and antiretroviral (ARV) and non-ARV medicines used and criteria for initiation of treatment were similar. The number of patients on ART was used as a criterion for inclusion of the hospitals and the health centers. To be included in the study, a health center had to enroll at least 10 ART-naive patients every month during the 6 months prior to follow-up period chosen. For the hospitals, a lower limit of enrolling 40 new HIV-positive persons on treatment every month in the preceding 6 months was used as a criterion for inclusion. A zonal hospital, a district hospital, and 3 health centers fulfilled the criteria and were ultimately selected for the study.
Individual patient records and standardized pre-ART and ART registers of patients followed up for 24 months (February 2007 to February 2009) were reviewed by the author. From the records, initiation of ART less than 6 months prior to the follow-up period at any site was taken as a participant inclusion criterion. Patients who enrolled in chronic HIV care during the same period but did not begin ART were excluded from the study.
According to the national ART guidelines, a team of 2 ART-trained physicians (at least 1 specialist in internal medicine), 2 ART-trained nurses, 2 data clerks, and 2 pharmacists are required to run a zonal hospital ART clinic. In the same vein, the guidelines recommend 2 ART-trained health officers, 2 ART-trained nurses, 1 data clerk, and 2 pharmacy technicians as members of an ART team at health center level.
17 Health officers are mid-level health care professionals trained for 3 years to work at health center level.
In Ethiopia, the eligibility criteria for ART is a CD4 count below 200 cells/mm 3 or WHO clinical stages III and IV (in the absence of CD4 count). Viral load is not routinely determined in any of the ART sites. First-line ARV regimens used in Ethiopia comprise lamivudine (3TC)/nevirapine (NVP)/zidovudine (ZDV). Alternative regimens include stavudine (d4T)/3TC/efavirenz (EFV), and a few other combinations. 18 The outcome in this study was defined as the category assigned to an ART patient after a 24-month follow-up. On reviewing the individual patient medical records and standardized ART registers, the following outcomes assigned to the patients were noted: patients who were alive and were taking ART and those who were no more on treatment at the study site. The patients who were no longer on treatment at the study site were assigned one of the following outcomes: lost to follow-up (LTFU); stopped treatment (ST); transferred out (TO); or died (D). A patient who was late from last appointment by more than 3 months was assigned an outcome of ''lost to follow-up.'' ''Stopped treatment'' was the outcome given to a patient who could be traced but informed the ART nurse or physician that he or she was no longer on any ARV medicine. A patient who was sent to another health facility for clinical or social reasons with a documented referral paper was considered ''transferred out.'' A patient whose death was reported by any member of the family and documented in ART registers was considered ''dead.'' A documented follow-up visit within the preceding 3 months was sufficient to qualify the patient as ''alive and on treatment.'' Patients who were receiving ART could be either improving or not improving. ''On treatment and improving'' (OTI) were patients whose CD4 count increased at least by 50 cells/mm 3 within the first 6 months or no AIDS-defining illness (WHO stage III or IV illness) was documented at the last visit, and patients ''on treatment and not improving'' (OTN) were those whose CD4 count did not raise by 50 cells/mm 3 during the first 6 months of the follow-up or AIDS-defining illness was documented at the last visit. 15 Any patient who was switched to a second-line ARV regimen was categorized as ''on treatment and not improving. '' 19 Approval to conduct the study was obtained from the local ethical review committee at the Oromia Regional Health Bureau. In addition, permission to conduct the study was obtained from the leadership at each ART site.
The data were entered during the study and processed and analyzed using Statistical Package for the Social Sciences (SPSS) software for Windows version 16. The outcomes of ART at 2 hospitals and 3 health centers were compared. The chi-squared test was used to check whether there was a statistically significant association of treatment levels with outcomes of ART. Statistically significant associations and comparisons were taken at P value less than .05.
Results
Outcomes of ART were compared between patients at hospitals and health centers of the Oromia region of Ethiopia. As presented in Table 1 , Adama zonal hospital is an urban treatment site and Bishoftu district hospital is a rural site. Similarly, Mojo and Holeta health centers are rural and Sebeta is an urban health center. Adama had the highest number of health professionals working in the ART clinic. It had 2 ART-trained physicians and 5 ART-trained nurses regularly working in the ART clinic. In addition, Bishoftu hospital had a health officer and a nurse regularly working in the ART clinic. The ART clinic at each health center was staffed by 1 health care professional, a health officer at Mojo, and a nurse at Holeta as well as at Sebeta health centers. With regard to ART safety monitoring machines, FACSCount Apparatus (for CD4 counts), hematology, and chemistry analyzers were available at Adama hospital. All the remaining sites had to transport blood samples to other laboratory centers for CD4 determination and other related tests.
Between September 2006 and February 2007, 1709 HIVpositive patients were started on ART at 2 hospitals and 3 health centers in the Oromia region of Ethiopia. Of these patients, 1044 (61%) remained alive and on treatment after a 24-month follow-up. The 2 hospitals enrolled 1457 (85 %) patients as compared to 252 (15%) patients at the 3 health centers. The study also demonstrated that while 835 (57%) patients at hospitals were alive and on treatment after the 24-month follow-up, 209 (83%) patients at health centers were assigned the same outcome (relative risk [ The proportion of patients lost to follow-up was highest at Adama hospital (24%) and lowest at Sebeta health center (7%; Table 2 ). At hospitals, there was a small difference between men (23%) and women (22%) lost to follow-up. However, at health centers, the proportion of men lost to follow-up was 12% and that of women was 8%.
Similar analysis revealed that the proportion of patients died was higher at hospitals (11%) than at health centers (5%). A further gender analysis indicated that 11% of the men and 10% of the women died during the 24-month follow-up (Table 3) .
Baseline CD4 count was determined for 1528 (89%) patients. It was also a medical eligibility criterion to initiate ART for 92% patients at hospitals and 74% of patients at health centers. Overall, at the initiation of ART, the median CD4 count was 130 cells/mm 3 and it increased to 283 cells/mm 3 after 6 months. The median CD4 count before ART initiation was 130 cells/mm 3 for patients at hospitals and 138 cells/mm 3 for patients at health centers. However, CD4 determined after 6 months of treatment showed a median CD4 count of 297 cells/ mm 3 and 253 cells/mm 3 for patients at hospitals and health centers, respectively.
While the median age of the patients was 33 years, 102 (6%) children (<15 years of age) were receiving ART at the sites. Overall, 41% of the patients were men. A gender-specific analysis of the data demonstrated that 631 (62%) women and 413 (59%) of men were alive and remained on treatment. Similarly, after 24-month follow-up, the proportion of men on treatment and improving (72%) was about the same as that of women who were improving (75%). Individual patient card review at the sites revealed that 79% of patients at health centers and 72% at hospitals were clinically or immunologically improving ( Table 3 ). The result also showed that the proportion of patients whose ARV medicines were either switched to alternate regimen or shifted to second-line treatment were higher at hospitals 95 (8) 17 (6) 19 (19) 26 (33) 18 (29) 112 (8) 63 (26) CD4 count done, N (%)
1078 (82) 271 (94) 81 (81) 53 (67) 45 (71) 1349 (92) 179 (74) Total started on ART, N (%)
1169 (100) 288 (100) 100 (100) 79 (100) 73 (100) 1457 (100) 252 (100)
Outcome the patient was assigned after a 24-month follow-up Currently alive and on ART at the site, N (%)
647 (55) 188 (65) 79 (79) 69 (87) 61 (84) 835 (57) 209 (82) Lost to follow-up or stopped, N (
285 (24) 46 (17) 11 (11) 8 (10) 5 (7) 331 (23) 24 (10) Died, N (%)
122 (11) 42 (14) 6 (6) 2 (3) 3 (4) 164 (11) 11 (5) Transferred out, N (%)
115 (10) 12 (4) 4 (4) 0 (0) 4 (5) 127 (9) 8 (3) Type of ARVs used after a 24-month follow-up period Currently alive and on ARV medicines, N (%)
647 (100) 188 (100) 79 (100) 69 (100) 61 (100) 835 (100) 209 (100) No on original first-line ARV regimen at the site, N (%)
493 (76) 138 (73) 73 (92) 67 (97) 59 (96) 631 (76) 199 (95) No on alternate first-line ARV regimen (substituted), N (%)
149 (23) 47 (25) 6 (8) 2 (3) 2 (4) 196 (23) 10 (5) No on second-line ARV regimen (switched), N (%)
5 (1) 3 (2) 0 (0) 0 (0) 0 (0) 8 ( (24%) than health centers (5%). While no patient at the health center level was on the second-line ARV regimens, 1% of hospital patients had their ARV medicines switched to second-line regimens.
Discussion
Ethiopia has made a significant headway with the expansion of access to care and treatment for its huge HIV-positive population. By December 2008, 175 612 HIV-positive persons in Ethiopia were enrolled on treatment in 93 hospitals and 274 health centers. Two years after several health facilities started rendering ART service, overall retention in the program was 73%. 20 The current study examined whether there was a difference in outcomes on ART at hospital and health center levels and explored barriers to patient retention on treatment. The hospitals included in the study had an adequate number of ART-trained health providers. However, only 1 trained health provider was responsible for the ART at each health center included in the study. In addition, patient enrollment on ART was higher at hospitals than health centers in absolute numbers. It is, however, worth noting, that there was no considerable difference in retention on treatment between urban and rural sites.
A total of 1709 HIV-positive patients started on ART at 2 hospitals and 3 health centers within 6 months. Of these patients, 1044 (61%) remained alive and on treatment after 24-month follow-up. This was considerably lower than a report from South Africa that showed 72% adult retention rate after 4 years on ART. 16 Not surprisingly, the 2 hospitals enrolled more patients, 1457 (85%), than the 3 health centers, 252 (15%). However, while only 835 (57%) of patients at hospitals were alive and on treatment after the 24-month follow-up, 209 (83%) of ART patients at health centers were retained in the program (RR at 95% CI: 3.621 [2.566-5.108]). Of 1709 HIV-positive patients initiated on ART, 361 (21%) were lost to follow-up within 24 months. This proportion was higher than a 2-year follow-up report (8%) from residents of an urban slum of Nairobi, Kenya, 21 and 1-year experience of similar program in Malawi (8%). 22 In a similar vein, the analysis of outcomes by treatment levels revealed that 331 (23%) patients at hospitals were lost to follow-up as compared to only 24 (10%) patients at health centers (RR at 95% CI: .358 [.231-.555]). This finding is in line with a report from a similar program in South Africa, which also showed a higher loss to follow-up at a hospital than at lower level clinics. 14 Higher patient attrition at hospitals could be due to financial burden of longer distance travel and longer missed work hours, 5 ineffective adherence counseling, and spotty follow-up at hospitals. Anecdotal evidence also suggested that patient counseling and follow-up are inadequate at hospital due to a higher work load of the staff. Site-specific analysis of 2 urban centers showed that Adama had the highest rate of loss to follow-up (24%) and Sebeta had the lowest (7%), supporting the assumption that level difference played a role in patient retention. The proportion of patients transferred out to other sites was also higher at hospitals (8%) than at health centers (3%) due likely to accelerated expansion of health center ART sites (RR at 95% CI: .343 [.166-.711]; Table 4 ).
At hospitals, the proportion of men (23%) lost to follow-up was barely higher than that of women (22%). However, at health centers, the proportion of men lost to follow-up was 12% and that of women was 8%. Overall, 175 (10%) patients died during the 24-month follow-up and more deaths were expected among those who were lost to follow-up. The mortality rate was much higher than a 2-year follow-up report (4%) from Kenya. 21 However, mortality rate in this study was lower than the report from similar settings in South Africa, which showed that 17% of patients at clinics and 14% patients at a hospital died during a 15-month follow-up.
14 Treatment level-specific analysis revealed that the proportion of patients died was higher at hospitals (11%) than health centers (5%; RR at 95% CI: .360 [.192-.673]). It is likely that patients with an advanced stage of the disease preferred hospitals for ART, which increased the mortality rate. In addition, the genderspecific analysis of 24-month follow-up indicated that 11% of men and 10% of women died.
A total of 1528 (89%) patients initiated ART based on CD4 count. Analysis based on treatment levels also indicated that 92% of patients at hospitals and 74% of patients at health centers had baseline CD4 count. The absence of FACSCount Apparatus at health centers might explain the lower proportion (10) 11 (4) 8 (3) 209 (100) 166 (79) 43 (21) Abbreviations: D, died; LTFU, lost to follow-up; OTI, on treatment and improving; OTN, on treatment and not improving; ST, stopped treatment; TO, transferred out.
of patients with baseline CD4 count. In this study, the 130 cells/mm 3 baseline median CD4 count increased to 283 cells/ mm 3 after 6 months. While the baseline median CD4 count was higher than the result (105 cells/mm 3 ) from a rural center in Cameroon, the increase in median CD4 count was comparable to report from the same study. 23 Initial test results in this study showed median CD4 count of 130 cells/mm 3 at hospitals and 138 cells/mm 3 at health centers. It is likely that patients with advanced disease and low CD4 count were enrolled at hospitals. However, CD4 determined after 6 months of treatment showed a median CD4 count of 297 and 253 cells/mm 3 at hospitals and health centers, respectively (Table 5) .
In general, the proportion of women (59%) starting on ART was higher than men (41%). A higher HIV prevalence in women than men and accessible prevention of mother-tochild-transmission services could explain a higher proportion of women enrolling. The proportion of men starting on ART in this study was higher than the proportion (30%) reported from South Africa. 16 A similar analysis demonstrated that 631 (62%) women and 413 (59%) men were alive and remained on treatment. In addition, of those who were alive and on treatment, 72% of men and 75% of women were improving. Clinical or immunological improvement was established in 79% of patients at health centers and 72% of patients at hospitals. A study with the same follow-up time in South Africa reported that 52% to 76% of the patients were in care and responding to ART. 15 A review of the most recent utilization of ARV medicines showed that 80% of patients were on first-line ARV regimens, 19% on alternate regimens, and 1% on second-line treatment. The proportion of patients whose ARV medicines were either switched to alternate regimen or shifted to second-line treatment were higher at hospitals (24%) than health centers (5%) possibly because health centers referred patients who had major side effects or treatment failure to hospitals. The rate of prescription of second-line ARV regimens in this study was lower than the 3.7% reported from South Africa after 2 years of an ART program. 16 In this study, several limitations were noted. The sites included in the study were few and they cannot represent all health facilities in Ethiopia. Consequently, care should be taken to draw a conclusion and generalization, and transfer to other settings needs further study of a larger scale. In addition, it is likely that the general condition of the patients going to hospitals and health centers was different and it might be difficult to compare outcomes of ART especially ''died'' at the 2 levels. It was also possible that AIDS-defining illnesses nonuniformly affected the ''died'' outcome at the 2 levels. Moreover, it was difficult to determine whether all the documented deaths were related to HIV. CD4 count could be used as one of the metrics in monitoring patient response to ART. However, AIDSdefining illnesses during the last visit could not substitute CD4 count increase at 6 months.
Despite the limitations noted, the study provided evidence of good ART outcomes at health centers. Patient retention in the program is better at health centers than hospitals, reinforcing the assumption that decentralization of ART, would be feasible without compromising the outcome of the services. In addition, expansion of the service to more health centers, establishing patient support groups, and more involvement of PLHIVs in peer counseling may well have imperative impact on patient retention in ART program.
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